MediWound (NASDAQ:MDWD) Releases Earnings Results, Beats Estimates By $0.58 EPS

MediWound (NASDAQ:MDWD - Get Free Report) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.58, Zacks reports. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same period in the prior year, the firm earned ($1.05) EPS. MediWound updated its FY 2025 guidance to EPS.

MediWound Price Performance

Shares of NASDAQ MDWD traded down $0.72 during mid-day trading on Wednesday, hitting $20.15. The company had a trading volume of 23,377 shares, compared to its average volume of 90,777. The business's 50-day simple moving average is $17.39 and its 200-day simple moving average is $17.58. MediWound has a 12 month low of $12.78 and a 12 month high of $24.00. The firm has a market cap of $217.78 million, a P/E ratio of -6.95 and a beta of 0.30.

Institutional Investors Weigh In On MediWound

An institutional investor recently raised its position in MediWound stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in MediWound Ltd. (NASDAQ:MDWD - Free Report) by 22.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,452 shares of the biopharmaceutical company's stock after buying an additional 999 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.05% of MediWound worth $85,000 at the end of the most recent reporting period. Institutional investors own 46.83% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on MDWD. StockNews.com raised shares of MediWound to a "sell" rating in a research note on Friday, March 21st. HC Wainwright reaffirmed a "buy" rating and issued a $25.00 price target on shares of MediWound in a research note on Thursday, March 20th. Alliance Global Partners assumed coverage on shares of MediWound in a research report on Friday, May 2nd. They set a "buy" rating and a $25.00 target price on the stock. Finally, Craig Hallum assumed coverage on shares of MediWound in a research report on Friday, February 28th. They set a "buy" rating and a $39.00 target price on the stock. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $29.75.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.